Feature | May 19, 2014

ECG for Pre-Participation Screening of High School Athletes Efficient at Finding Heart Abnormalities

Largest study to use modern interpretation criteria of ECGs led to more accurate detection of cardiac conditions


May 19, 2014 — A new study found that adding an electrocardiogram (ECG) to existing pre-participation screening of high school athletes increases the likelihood of identifying disorders associated with sudden cardiac death. By using modern interpretation criteria, screenings resulted in fewer false-positive rates, which leads to more accurate detection. The findings were presented at Heart Rhythm 2014, the Heart Rhythm Society’s (HRS) 35th annual scientific sessions.

The prospective study was conducted at 23 high schools in the greater Seattle area from October 2010 through June 2013. Competitive athletes ages 13 to 19 underwent a screening protocol that included a heart health questionnaire and physical recommendations based on the current American Heart Assn. (AHA) recommendations, as well as a resting 12-lead ECG interpreted using athlete-specific criteria and limited echocardiogram.

Nearly 5,000 (4,812) athletes were screened, and 23 athletes were identified with a significant abnormality requiring further evaluation. Abnormal history or physical examination findings led to a diagnosis in 61 percent of disorders, and an abnormal ECG led to a diagnosis in 70 percent. The addition of ECG led to detection in seven (30 percent) athletes not otherwise identified by AHA protocol.

“The debate has mostly been focused on whether or not to include ECG screening, and this study shows it is not just about whether or not to include an ECG, but the importance of appropriate ECG interpretation in athletes,” said lead author Jordan M. Prutkin, M.D., MHS, FHRS, assistant professor at the University of Washington School of Medicine Center for Sports Cardiology. “We need to focus future research on how we can further develop better athlete-specific interpretation criteria, which in turn will help reduce sudden cardiac arrest in the young population.”

While the history and physical exam are important and recommended by AHA, the study found that these alone gave more false positive readings than the ECG. The ECG had a significantly lower false positive rate at 3.6 percent, when compared to the history (22.3 percent) and physical exam (14.9 percent). In addition, the ECG was better at positively predicting abnormalities than the history and physical examination. When modern interpretation criteria is used, ECG screening increases the likelihood of detecting disorders associated with sudden cardiac death and may help ease anxiety about the results of the ECG screening and reduce associated costs. An integrated screening protocol using history, physical examination and ECGs should be considered for pre-participation screening in young athletes.

For more information: www.hrsonline.org


Related Content

News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
Subscribe Now